Pilot Study of Magnesium Infusions in Pediatric Asthma
| Status: | Withdrawn |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 2 - 20 |
| Updated: | 3/31/2017 |
| Start Date: | January 2012 |
| End Date: | October 2013 |
A Pilot Study of Magnesium Infusions (Drips) for Moderate-to-Severe Pediatric Asthma Exacerbations
This is a prospective randomized pilot study that seeks to address the research question: In
children with moderate-to-severe asthma, do intravenous magnesium infusions added to
standard Pediatric intensive care unit (PICU)-level asthma care significantly decrease time
from patient presentation until PICU discharge?
children with moderate-to-severe asthma, do intravenous magnesium infusions added to
standard Pediatric intensive care unit (PICU)-level asthma care significantly decrease time
from patient presentation until PICU discharge?
This study will be a double-blind, prospective randomized pilot study. Subjects will be
randomized on a 1:1 basis to receive routine asthma care with or without a magnesium drip.
randomized on a 1:1 basis to receive routine asthma care with or without a magnesium drip.
Inclusion Criteria:
- Age 2 years 0 days up to 20 years 364 days
- Clinical diagnosis of asthma including both of the following:
- Attending physician's primary working diagnosis is status asthmaticus
- Results of a modified International Study of Asthma and Allergies in Children
(ISAAC) diagnostic questionnaire consistent with an asthma diagnosis
- Planned PICU admission for moderate-to-severe asthma exacerbation persisting despite
standard first-tier therapy (systemic corticosteroids and at least a one-hour
treatment with nebulized albuterol/ipratroprium or equivalent) as evidenced by an
asthma score of 7 or greater
- IV access or equivalent
- Ability to understand and give informed consent/assent in English
Exclusion Criteria:
- Prior enrollment in this study
- Prior adverse reactions to magnesium
- Use of systemic corticosteroids or magnesium in preceding 2 weeks, or administered at
a transferring facility more than 3 hours prior to enrollment
- Admission for inpatient asthma care in preceding 2 weeks
- Hemodynamic instability, impending respiratory failure or intubation
- Inability in children age 7 years or older to give assent due to a developmental
delay or altered mental status
- Significant renal or cardiac disease
- Sickle cell anemia
- Significant, active non-asthma pulmonary disease
We found this trial at
1
site
Kosair Children's Hospital For more than a century, Kosair Children's Hospital and its predecessor hospitals...
Click here to add this to my saved trials
